# Program 04 Leukemia

> **NIH NIH P30** · DANA-FARBER CANCER INST · 2024 · $41,118

## Abstract

Leukemia Program
Project Summary / Abstract
The mission of the Leukemia Program is to improve patient outcomes through innovative translational research
on acute and chronic leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, and antecedent
premalignant states. Our longstanding objectives are to (a) discover cell-intrinsic and microenvironmental
drivers of these conditions, and (b) translate laboratory discoveries into investigator-initiated early-phase
clinical trials. To develop novel therapeutics, Program members leverage effective and fruitful collaborations
between leukemia biologists, chemists, immunologists, and clinicians. These interactions depend critically on
the Cancer Center’s collaborative infrastructure, shared resources, outstanding systems for clinical trial review
and conduct, and the deep culture of bench-to-bedside investigation across the consortium. Community
outreach and training in cancer research are deeply embedded in the Program’s laboratory, translational, and
clinical efforts.
The Program’s 89 members (69 primary and 20 secondary) represent six DF/HCC institutions and 10
academic departments. In 2019, peer-reviewed grant funding attributed to the Program was $8.9 million in
direct costs from the NCI and $8.3 million from other sponsors. During the current funding period, primary
Program members published 1,129 cancer-relevant papers. Of these, 27% were inter-institutional, 26% were
intra-programmatic, and 41% were inter-programmatic collaborations between two or more DF/HCC members.
For the next CCSG funding period, we propose the following two Specific Aims: 1) Identify novel mechanisms
that contribute to the pathogenesis of acute leukemias, myelodysplastic syndromes, myeloproliferative
neoplasms and premalignant states, and 2) Advance therapeutics that target vulnerabilities in these diseases.

## Key facts

- **NIH application ID:** 10768663
- **Project number:** 5P30CA006516-59
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** Andrew A Lane
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $41,118
- **Award type:** 5
- **Project period:** 1997-03-10 → 2026-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10768663

## Citation

> US National Institutes of Health, RePORTER application 10768663, Program 04 Leukemia (5P30CA006516-59). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10768663. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*